Survival Probability in Multidrug Resistant Pulmonary Tuberculosis Patients in a South Indian Region

IF 0.8 Q4 PHARMACOLOGY & PHARMACY
Thungathurthi Smitha, Pantham Sunitha, O. Prabhakar, Sindgi Vasudeva Murthy
{"title":"Survival Probability in Multidrug Resistant Pulmonary Tuberculosis Patients in a South Indian Region","authors":"Thungathurthi Smitha, Pantham Sunitha, O. Prabhakar, Sindgi Vasudeva Murthy","doi":"10.1177/00185787231224065","DOIUrl":null,"url":null,"abstract":"Background: Drug-resistant tuberculosis is a burgeoning threat to public health requiring novel strategies to combat the infection. Although national tuberculosis elimination programs focus on improving health services, challenges in eradicating tuberculosis still exist. Factors attributing to unfavorable outcomes are unknown in Warangal district of Telangana state. Methods: This study included 296 patients diagnosed with multidrug-resistant pulmonary tuberculosis. The study participants followed up for a maximum of 20 months to determine treatment outcomes. Statistical applications of Kaplan-Meier curve and log-rank test used to find the survival probabilities in subgroups. Results: The survival of multidrug-resistant pulmonary tuberculosis patients was ascertained, in male and female patients, aged between 31 and 50 years. Resistance to rifampicin was prominent. The study found a survival rate of 76.68% and a mortality rate of 23.31%. The log-rank test revealed a significant difference in survival in subcategories with and without comorbidities ( P = .03), non-adherence to treatment ( P = .0001), treatment duration ( P = .02), regimens ( P = .01), and grading of radiograph ( P = .0001). Conclusion: This study identified factors that influenced the survival probability of multidrug-resistant pulmonary tuberculosis patients, including comorbidities, weight band, non-adherence to treatment, treatment duration, regimens, and grading of radiograph. These findings emphasize the need for enhanced management strategies to improve treatment outcomes.","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00185787231224065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Drug-resistant tuberculosis is a burgeoning threat to public health requiring novel strategies to combat the infection. Although national tuberculosis elimination programs focus on improving health services, challenges in eradicating tuberculosis still exist. Factors attributing to unfavorable outcomes are unknown in Warangal district of Telangana state. Methods: This study included 296 patients diagnosed with multidrug-resistant pulmonary tuberculosis. The study participants followed up for a maximum of 20 months to determine treatment outcomes. Statistical applications of Kaplan-Meier curve and log-rank test used to find the survival probabilities in subgroups. Results: The survival of multidrug-resistant pulmonary tuberculosis patients was ascertained, in male and female patients, aged between 31 and 50 years. Resistance to rifampicin was prominent. The study found a survival rate of 76.68% and a mortality rate of 23.31%. The log-rank test revealed a significant difference in survival in subcategories with and without comorbidities ( P = .03), non-adherence to treatment ( P = .0001), treatment duration ( P = .02), regimens ( P = .01), and grading of radiograph ( P = .0001). Conclusion: This study identified factors that influenced the survival probability of multidrug-resistant pulmonary tuberculosis patients, including comorbidities, weight band, non-adherence to treatment, treatment duration, regimens, and grading of radiograph. These findings emphasize the need for enhanced management strategies to improve treatment outcomes.
南印度地区耐多药肺结核患者的生存概率
背景:耐药性结核病对公共卫生的威胁日益严重,需要采取新的策略来抗击这种感染。尽管国家消灭结核病计划的重点是改善医疗服务,但消灭结核病的挑战依然存在。在特兰甘纳邦的瓦兰加尔区,导致不利结果的因素尚不清楚。研究方法这项研究包括 296 名确诊为耐多药肺结核的患者。研究人员对患者进行了长达 20 个月的随访,以确定治疗结果。采用 Kaplan-Meier 曲线和对数秩检验进行统计,以确定亚组的生存概率。结果显示确定了耐多药肺结核患者的存活率,男性和女性患者的年龄在 31 岁至 50 岁之间。对利福平的耐药性十分突出。研究发现,存活率为 76.68%,死亡率为 23.31%。对数秩检验显示,在有合并症和无合并症(P = .03)、不坚持治疗(P = .0001)、治疗时间(P = .02)、治疗方案(P = .01)和放射学检查分级(P = .0001)等子类别中,存活率存在显著差异。结论本研究确定了影响耐多药肺结核患者生存概率的因素,包括合并症、体重带、不坚持治疗、治疗时间、治疗方案和放射学检查分级。这些发现强调了加强管理策略以改善治疗效果的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hospital Pharmacy
Hospital Pharmacy PHARMACOLOGY & PHARMACY-
CiteScore
1.70
自引率
0.00%
发文量
63
期刊介绍: Hospital Pharmacy is a monthly peer-reviewed journal that is read by pharmacists and other providers practicing in the inpatient and outpatient setting within hospitals, long-term care facilities, home care, and other health-system settings The Hospital Pharmacy Assistant Editor, Michael R. Cohen, RPh, MS, DSc, FASHP, is author of a Medication Error Report Analysis and founder of The Institute for Safe Medication Practices (ISMP), a nonprofit organization that provides education about adverse drug events and their prevention.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信